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Abstract
Autoimmune pancreatitis is frequently associated with elevated serum and tissue IgG4 levels in the adult
population, but there are few reports of pediatric autoimmune pancreatitis, and even fewer reports of IgG4 related
systemic disease in a pediatric population. The standard of care treatment in adults is systemic corticosteroids with
resolution of symptoms in most cases; however, multiple courses of corticosteroids are occasionally required and
some patients require long term corticosteroids. In these instances, steroid sparing disease modify treatments are
in demand. We describe a 13-year-old girl with IgG4 related systemic disease who presented with chronic
recurrent autoimmune pancreatitis resulting in surgical intervention for obstructive hyperbilirubinemia and chronic
corticosteroid treatment. In addition, she developed fibrosing medianstinitis as part of her IgG4 related systemic
disease. She was eventually successfully treated with mycophenolate mofetil allowing for discontinuation of
corticosteroids. This is the first reported use of mycophenolate mofetil for IgG4 related pancreatitis. Although
autoimmune pancreatitis as part of IgG4 related systemic disease is rarely reported in pediatrics, autoimmune
pancreatitis is also characterized as idiopathic fibrosing pancreatitis. All pediatric autoimmune pancreatitis cases
reported in the world medical literature were identified via a PUBMED search and are reviewed herein. Twelve
reports of pediatric autoimmune pancreatitis were identified, most of which were treated with corticosteroids or
surgical approaches. Most case reports failed to report IgG4 levels, so it remains unclear how commonly IgG4
related autoimmune pancreatitis occurs during childhood. Increased evaluation of IgG4 levels in patients with
autoimmune pancreatitis may shed further light on the association of IgG4 with pancreatitis and the underlying
pathophysiology.
Background
The concept of immune mediated pancreatitis was first
suggested by Sarles et al. in 1961 after observing massive
lymphoplasmocytic infiltrates and fibrosis on pancreatic
histology in patients with pancreatitis of unknown etiol-
ogy [1]. Autoimmune pancreatitis (AIP) was further
documented and characterized by Yoshida et al. in 1995
[2] with 11 common characteristics that have become
the basis for diagnostic criteria of AIP [3-5] (Tables 1
and 2). These criteria are based on characteristic
changes seen on imaging, pathology, serology, and
disease modification (and usually resolution) with corti-
costeroid treatment [2-5]. When Hamano et al. identified
an abnormal fraction of gamma globulins in patients
with AIP in 2001, elevated serum IgG4 level became the
hallmark lab value for AIP in adults [6]. Since then there
have been many reports of adults with isolated AIP and
multisystem sclerosis with elevated IgG4 levels [7]. How-
ever, there have been very few reports of pediatric
patients with AIP [8-13], and all of those have had nor-
mal or not reported IgG4 levels. There is one report of a
pediatric patient with elevated IgG4 levels; however, she
did not have imaging changes or histology available to
make a more definitive diagnosis of AIP [14]. Herein, an
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(JPS) 2006 criteria [4] (Table 1) and Mayo Clinic HISORt
criteria [3,5] (Table 2)] with elevated IgG4 levels and evi-
dence of systemic disease treated successfully with myco-
phenolate mofetil (MMF) is reported. A review of the
literature on the topic of IgG4 related systemic disease
and AIP in childhood is included.
Case Presentation
A 13-year-old Caucasian female with chronic abdominal
pain initially developed fever, headache, and joint symp-
toms. Her symptoms persisted and progressed until she
was hospitalized for shortness of breath several months
later after developing what appeared to be a right lung
scar and pericardial effusion by imaging. She was also
diagnosed with pancreatitis and jaundice with a serum
bilirubin level of 4.5 mg/dL. A computerized tomogra-
phy (CT) scan revealed multiple pancreatic masses and
biliary dilatation, lab work revealed an elevated IgG4,
and she was transferred to our institution for further
work up and management. Because of her persistent
and recurrent pancreatitis symptoms, along with abnor-
mal imaging she was diagnosed with AIP, meeting both
JPS criteria (criterion 1 and criterion 2) and HISORt cri-
teria (group B and after initiation of steroids, group C).
Radiographic imaging [endoscopic ultrasound (EUS) and
endoscopic retrograde cholangiopancreatography
(ERCP)] and surgical placement of a pancreatic stent
were performed. Prior to stent placement her serum
lipase was elevated at 313 U/L (10-180). Other signifi-
cant laboratory findings included the following results:
amylase 39 U/L (39-100), AST 106 U/L (10-30), ALT 88
U/L (10-30), and alkaline phosphatase 417 U/L (93-386).
EUS/ERCP revealed a stricture at the distal common
bile duct, multiple focal hyperechoic areas in the pan-
creas with benign fine needle aspirate (FNA) consistent
with chronic pancreatitis (specifically revealing a
lymphocytic inflammatory infiltrate; no staining was
performed on pancreatic aspiration specimens because
there was insufficient sample), and a pancreatogram
consistent with chronic pancreatitis (stricture of distal
common bile duct and biliary dilatation). Following
stent placement her lipase improved to 84 U/L. The
stent was removed two months later as previously
scheduled, and shortly after the procedure she devel-
oped worsening abdominal pain. A CT of the abdomen
demonstrated dilatation of the intrahepatic and extrahe-
patic bile ducts without evidence of choledocholithiasis,
mild dilation of the pancreatic duct and multiple foci of
hypodensity within the kidneys. Her bilirubin level and
liver function tests began to increase. One week after
stent removal she was taken back for an ERCP and
another stent was replaced. Her pain and jaundice
improved, and the liver enzymes quickly returned to
normal. When her stent was removed for the second
time, multiple brushings and biopsies were taken.
Pathology on duodenal biopsies revealed marked expan-
sion of atypical lymphoid tissue, positive staining for
CD20, BCL-6, BCL-2, CD10, and KI-67 and negative for
CD5, CD23, Tdt, BCL-1, and CD30. cMYC translocation
was negative and there was a light chain but not heavy
chain rearrangement present. IgG4 staining was not
done on this sample. This immunochemistry suggested
a diffuse large B cell lymphoma; however, follow up on
following FNA, biopsy and imaging did not demonstrate
a monoclonal lymphoid population nor suggest malig-
nancy. Autoantibody studies were all negative including:
ANA, anti-dsDNA, anti-smooth muscle antibodies, anti-
RNP, SSA/SSB autoantibodies, scleroderma-70 antibo-
dies, and ANCA. In addition, C3, C4, and angiotensin
converting enzyme levels were within normal limits for
age. She returned again in 3 months for stent removal
which she tolerated well. EUS revealed calcifications in
the head of the pancreas (a finding that is unusual for
Table 1 Clinical diagnostic criteria of Autoimmune Pancreatitis as proposed by the Japanese Pancreas Society,
revised 2006 (4)
1. Diffuse or segmental narrowing of the main pancreatic duct with irregular wall and diffuse or localized enlargement of the pancreas by imaging
studies, such as abdominal ultrasonography, computed tomography, and magnetic resonance imaging.
2. High serum gamma-globulin, IgG, or IgG4, or the presence of autoantibodies, such as antinuclear antibodies and rheumatoid factor.
3. Marked interlobular fibrosis and prominent infiltration of lymphocytes and plasma cells in the periductal area, occasionally with lymphoid follicles
in the pancreas.
Table 2 Mayo Clinic diagnostic groups with HISORt criteria (3,5)
Group
A:
Diagnostic pancreatic histology (presence of 1 or both of the following): Resection specimen or core biopsy showing the full spectrum of
changes of LPSP, and/or ≥ 10 IgG4 positive cells/hpf; IgG4 on immunostain of pancreatic lymphoplasmacytic infiltrate.
Group
B:
Typical imaging + serology (presence of all of the following criteria): CT or MRI showing diffusely enlarged pancreas with delayed and
“rim” enhancement; pancreatogram showing diffusely irregular pancreatic duct; elevated serum IgG4 levels.
Group
C:
Response to steroids (presence of all of the following criteria): Unexplained pancreatic disease after negative work-up for known etiologies
including cancer; elevated serum IgG4 levels and/or other organ involvement confirmed by presence of abundant IgG4-positive cells;
resolution/marked improved in pancreatic and/or extrapancreatic manifestations with steroid therapy.
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area of stranding within the mediastinum, consistent
with fibrosing mediastinitis. As treatment for her
pancreatitis, corticosteroids had been prescribed pre-
viously resulting in improvement of pain but with signif-
icant weight gain, and her abdominal pain/symptoms
would return shortly after tapering the corticosteroid
dose. At that time the rheumatology service was con-
sulted for the possibility of AIP.
To spare corticosteroids and to treat the IgG4-related
pancreatitis and mediastinitis, she was started on MMF
and tapered up to a maximum dose of 1,000 mg twice
daily. She improved quickly and remarkably with resolu-
tion of abdominal pain and the ability to return to an
enteral diet within days of starting MMF. The addition
of MMF allowed for significant improvement of symp-
toms, eventually in the absence of corticosteroids, as
well as normalization of laboratory and imaging findings
consistent with pancreatitis. In terms of her laboratory
findings, her lipase improved from 444 to 53 U/L (nor-
mal, 10-180) and amylase lowered from 63 to 41 U/L
within 3 days of MMF. The initial IgG4 level was 226
mg/dL (normal range, 11-157) prior to MMF; after
15 months of initiating treatment with MMF, the IgG4
subclass level was 73.4 mg/dL. Inflammatory markers,
ESR and CRP, were not measured until after treatment
was started, at which point they were within normal
limits. A repeat chest and abdominal CT one year after
initiating treatment did not reveal any residual mediast-
inal or hilar lymphadenopathy. There was no evidence
of pulmonary nodules or focal pancreatic lesions, and
there was resolution of the hypodense renal lesions and
fatty infiltration of the liver. She was ultimately tapered
off of all immunosuppressive therapy within 1 year of
treatment with MMF. The child currently remains in
good health off of all immunosuppressive medicine after
an additional period of over 7 months. She, thus, repre-
sents the first pediatric patient with AIP and elevated
IgG4 levels to be successfully treated with MMF allow-
ing for discontinuation of corticosteroids, and eventually
all immunosuppressive therapy.
Review of the AIP literature and focus on pediatric cases
Pancreatitis due to an inflammatory, autoimmune pro-
cess was first suggested by Sarles et al. in 1961 with the
description of 10 adult cases of chronic pancreatits, all
with massive cellular infiltrates and increased inflamma-
tion [1]. AIP was later named and described by Yoshida
et al. [2] in 1995 when a patient without evidence of
Sjogren syndrome developed pancreatitis and responded
to corticosteroid therapy. The patient had evidence of
autoimmune abnormality with a positive ANA titer,
anti-thyroglobulin antibody, and anti-microsomal anti-
bodies; all other autoantibodies tested were negative [2].
The authors described 11 characteristics of AIP that have
been used as the basis for the development of recent diag-
nostic criteria including; the JPS diagnostic criteria of AIP
[4] and the Mayo Clinic HISORt criteria [3,5] (Table 1).
Diagnostic criteria for AIP
Diagnostic criteria for AIP were first developed by the
JPS in 2002 and were revised in 2006 after reevaluating
additional patients with AIP and with likely AIP. The
foundation of the diagnosis rests on meeting characteris-
tic findings on imaging, along with supportive serology
and/or histology (Table 1). The JPS criteria emphasize
the importance of excluding malignancy during the
work up and the responsiveness to steroids, although
they did not include it as a diagnostic criterion [4]. The
Mayo Clinic, Chari et al. [3,5], used a cohort of patients
with AIP diagnosed by histology to develop criteria in
five categories that make 3 diagnostic groups (Table 2).
Those categories and criteria are: Histology, [at least
one of the following: periductal lymphoplasmacytic infil-
trate with obliterative phlebitis and storiform fibrosis
(LPSP) or lymphoplasmacytic infiltrate with storiform
fibrosis showing abundant (≥10 cells/hpf) IgG4-positive
cells]; Imaging, typically diffusely enlarged gland with
delayed (rim) enhancement, diffusely irregular, attenu-
ated main pancreatic duct or alternatively, focal
pancreatic mass/enlargement, focal pancreatic duct
stricture, pancreatic atrophy, pancreatic calcification, or
pan creatitis; Serology, elevated serum IgG4 level
(>140 mg/dL); Other organ involvement, hilar/intrahe-
patic biliary strictures, persistent distal biliary stricture,
parotid/lacrimal gland involvement, mediastinal lympha-
denopathy, retroperitoneal fibrosis; and response to
steroid therapy, resolution/marked improvement of pan-
creatic/extrapancreatic manifestations with steroid ther-
apy [3,5]. Of the previously diagnosed idiopathic
fibrosing pancreatitis (IFP) pediatric patients included in
this review, by imaging and histology, they are more
consistent with AIP, although immunoglobulin levels
were not measured and steroids were not given (surgi-
cally treated) in any of the cases [15-18] (Table 3).
Thus, for many pediatric patients reported in the litera-
ture to have IFP, it is difficult to establish whether they
meet AIP criteria.
Demographic and clinical characteristics of AIP
Typically, patients with AIP are older males; in one
study, 79% of patients were more than 50 years old (age
range 14-85 years) and 83% were male [3], and in
another study, the age range was 38-73 years old and
75% were male [6]. The patients usually presented with
obstructive jaundice [73% [3] and 65% [19]], weight loss
(35%) [19], and non-specific abdominal pain [35% [19]
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Case report Patient
and
demo-
graphics
Signs/
symptoms
Histology Imaging Serology (mg/dl) Other organ
systems
Response to
steroids
Treatment Outcome
AIP/likely
AIP
this report 13yo
female
fever,
headache,
joint pain,
vomiting,
epigastric
pain,
shortness of
breath,
weight loss,
jaundice
EUS-FNA consistent
with chronic
pancreatitis,
duodenal ampulla
enlarged, duodenal
biopsy with
atypical
lymphocytic
infiltrate
focal hypoechoic areas in
head, body, and tail of
pancreas with enlargement
of the head of the
pancreas, distal stricture of
CBD with biliary dilatation
IgG4 226, other
autoantibodies
negative
mediastinal
fibrosis,
pulmonary
nodules,
multiple
hypodense foci
in kidneys,
improvement
in pain, unable
to taper
without return
of symptoms
mycophenolate
mofetil
resolution of
symptoms and
abnormalities on
imaging,
normalization of
IgG4
Fukumori
et al. (14)
17yo
female
severe
epigastric
and back
pain
not done US, CT normal, MRCP-MPD
only in head of pancreas
IgG 2155, IgG4
157, positive
antilactoferrin Ab,
ANA 1:80
(speckled), other
autoantibodies
negative
none noted resolution of
pain, entire
MPD visualized
on MRCP,
disappearance
of ALF Ab
30 mg
prednisolone,
tapered off at 8
months
asymptomaticand
not currently
treated
Pace et al. (8) 18yo
male
recurrent
acute
pancreatitis
and
cholestasis
lymphocytes,
macrophages,
plasma cells
consistent with AIP
enlarged pancreatic head
on endoscopy
IgG4 23, ANA
1:320, other
autoantibodies
negative
none reported resolution of
symptoms
initially started
on
prednisolone
then tapered
off
asymptomatic
without further
treatment
Blejter et al. (9) 16yo
male
pruritus and
weight loss
chronic pancreatitis
with interstitial
periductal
lymphoplasmacytic
infiltration and
interstitial fibrosis
enlarged pancreatic head,
dilated biliary tract, no
passage of contrast into
duodenum on cholangio-
graphy
IgG4 normal,
hypogammaglob-
ulinemic, (no
specific values
given), other
autoantibodies
negative
none reported resolution of
symptoms,
repeat
cholangiogram
without biliary
dilatation or
stricture
prednisone 40
mg/kg/day then
tapered
no recurrence, he
requires NPH
insulin for
diabetes
Refaat et al.
(10)
11yo
male
nausea,
vomiting,
dull
epigastric
pain,
anorexia,
diarrhea
periductal fibrosis,
lymphocyte-plasmic
parenchymal
infiltrate
enlarged hypoechoic
pancreatic head (US),
hypointense surrounding
rim (MRI T2-W), diffuse
irregular narrowing of main
pancreatic duct
IgG4 and IgG
normal, (no
specific values
given), other
autoantibodies
negative
none reported not reported not reported not reported
Gargouri
et al. (11)
10yo
male
severe
abdominal
pain, biliary
vomiting,
weight loss
not done enlarged pancreas (US),
multiple stenoses of
Wirsung duct (MRCP),
multiple stenoses without
intracanalar lacuna and
stenosis of retropancrea-tic
segment of the bile duct
(ERCP)
IgG and IgG4
normal (no
specific values
given),
autoantibodies
negative
none reported resolution of
symptoms,
normalization
of pancreatic
size and
stenoses of
Wirsung duct
IV steroids 1
mg/kg/day ×
10 days then
decreased and
discontinued at
7 months
asymptomatic,
reported 4 years
after
discontinuation of
steroids
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9Table 3 Clinical characteristics of pediatric patients diagnosed with AIP and IFP (3-5) (Continued)
Takase et al.
(12)
14yo
female
severe right
upper
quadrant
pain
not done enlargement of pancreas
head to tail, homogeneous
low-echoic area with some
high-echoic spots inside
(US), enlargement of the
head of the pancreas (CT,
MRI), enlarged main
pancreatic duct with
narrow distal portion
(MRCP)
IgG 2104 (high)
IgG4 54, other
autoantibodies
negative
none reported improvement
in symptoms,
IgG, MRCP,
relapse × 2
(minimum)
initial dose IV
prednisolone 30
mg/day,
multiple tapers
and steroid
burst, required
daily treatment
multiple relapses
with subsequent
imaging changes,
no return of
elevated IgG
Bartholomew
et al. (13)
10yo
male
jaundice,
intermittent
abdominal
pain, fatigue,
weight loss
chronic pancreatitis
secondary to
lymphoplasmacytic
sclerosing
pancreatitis
pancreatic head mass with
likely invasion of portal
and superior mesenteric
veins (EUS)
not reported none reported not given Whipple
pancreatico-
duodenectomy
symptom free at
6 month follow
up, requires
digestive enzymes
Diagnosed
as IFP,
examples of
case reports
that could
be
consistent
with AIP
Atkinson
et al. (15)
10yo
male
epigastric
pain,
jaundice
fibrosis enclosing
normal acini, with
lymphocytes,
plasma cells, and
leukocytes between
acini
mass in pancreatic head
(laparotomy), obstruction
of CBD (IOC)
not reported none reported not given cholecysto-
duodenostomy
symptom free 15
years following
surgery
Elitsur et al.
(16)
2yo
female
abdominal
pain
fibrous
replacement of
pancreatic tissue,
preservation of
Islets of
Langerhans, with
polymorpho-
nuclear cells and
plasmalymph-ocytic
cells
enlarged pancreas with
dilatation of proximal bile
duct (US, CT), enlarged
nodular pancreas with
suggestion of
retroperitoneal mass (MRI)
ANA, anti smooth
muscle, anti
mitochondrial,
antithyroid
antibodies all
negative,
immunoglobulins
not reported
retroperitoneal
mass
not given ex-lap for
diagnosis,
spontaneous
resolution of
obstruction
repeat US
revealed normal
pancreas and CBD
Stephen et al.
(17)
7yo
male
jaundice,
lethargy,
weight loss,
prior to
jaundice
abdominal
cramping
and
vomiting
nodular aggregates
of lymphocytes
and plasma cells,
acinar tissue
replaced by dense
connective tissue
enlarged pancreas, head
less echogenic than the
rest of the pancreas,
dilated CBD with tapering
at the head of pancreas
(US)
negative ANA, no
other studies
reported
cholangitis,
pericholangitis
(similar
inflammatory
infiltrate)
not given Roux-en-Y
cholecysto-
jejunostomy,
incidental
appendectomy
symptom free
Keil et al. (18) 14yo
male
epigastric
pain,
jaundice
severe fibrosis with
chronic
lymphocytic
inflammatory
infiltrate
enlarged edematous head
of pancreas, dilated CBD
(US, CT), 2 cm stenosis of
CBD (ERCP)
“biochemical
parameters of
inflammatory
reactions were
normal”
none reported not given biliary stenting normal pancreas
by US after 12
months of
stenting,
symptom free 3.5
years following
treatment
Abbreviations used: AIP - autoimmune pancreatitis, EUS - endoscopic ultrasound, FNA - fine needle aspirate, CBD - common bile duct, US - ultrasound, CT - computed tomography, MRCP - magnetic resonance
cholangiopancreatography,
MPD - main pancreatic duct, Ab - antibody, ANA - antinuclear antibody, ALF - antilactoferrin antibody, MRI - magnetic resonance imaging, T2-W - T2 weighted images, ERCP - endoscopic retrograde
cholangiopancreatography, IOC - intraoperative cholangiogram.
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9narcotics [3]. In the pediatric case reports with a
diagnosis of AIP by JPS or HISORt criteria, the ages
ranged from 10-18 years old (above 18 years was con-
sidered an adult patient), and 62.5% were male [8-14]
(Table 3). If the IFP cases included in this review
are considered AIP, the pediatric age range becomes
2-18 years old and 66.7% of the patients were male
[8-18]. Clinically these patients (both AIP and IFP) pre-
sented with varying degrees of abdominal pain (10/12
patients, 83%), weight loss (5/12 patients, 42%), and
jaundice (5/12 patients, 42%) [8-18]. Abdominal pain is
more frequently a presenting symptom of AIP in pedia-
tric patients, like the one reported herein, than in adult
patients. In addition to clinical criteria, histopathologic
criteria have been developed to diagnose AIP.
Histopathology of AIP
Similar to the patient reported herein, needle biopsy of
the pancreas in the case report by Yoshida et al. [2]
revealed severe fibrotic change with lymphocytic infiltra-
tion. LPSP was the descriptive name of AIP prior to the
development of diagnostic criteria, a histologic pattern
distinct from ordinary chronic pancreatitis, alcoholic
pancreatitis, and obstructive pancreatitis secondary to
cancer. The histologic findings of AIP used to include
or exclude a diagnosis of AIP in case series and cohort
studies are a periductal lymphoplasmacytic infiltrate
with obliterative phlebitis and swirling fibrosis centered
around ducts and veins [3-5,19-25]. The majority of
lymphocytes are T cells, and eosinophils and neutrophils
can be found. In one study, all 3 patients with ulcerative
colitis were found to have neutrophilic infiltration of
pancreatic ducts [21]. Two subtypes of histologic inflam-
matory pattern were described, ductocentric and lobulo-
centric [21]. A similar dichotomy was described by
another group, interlobular lymphoplasmacytic inflam-
mation and idiopathic duct-centric chronic pancreatitis
(intralobular) [26]. Thus, the histopathologic findings in
AIP are rather varied.
Imaging findings in AIP
Both the JPS [4] and the Mayo HISORt [3,5] criteria
have specific imaging descriptions for AIP. A diffusely
enlarged pancreas on CT with diffuse irregular narrow-
ing of the pancreatic duct (both of which resolved fol-
lowing therapy) were included in the Yoshida et al.
original description of AIP [2]. In fact, diffuse irregular
narrowing of the pancreatic duct was part of the subjec-
tive differentiation between sclerosing pancreatitis with
elevated IgG4 levels and ordinary chronic pancreatitis
(irregular dilatation of the pancreatic duct or diffuse
calcification) for Hamano et al. [6]. Typically, AIP will
have imaging that reveals a “sausage-like” pancreas with
delayed enhancement on CT scan, rim enhancement on
T2 weighted MRI, or hypoechoic pancreas with echo-
genic spots on ultraound. AIP rarely causes calcification
or pancreatic pseudocyst, but can cause localized enlar-
gement which can contribute to the difficulty differen-
tiating it from malignancy [7]. The JPS criteria for
diagnosis of AIP require that pancreatic imaging is con-
sistent with AIP [4]. The Mayo Clinic HISORt criteria,
however, have 3 distinct diagnostic groups, only one of
which includes imaging criteria [3,5]. Both criteria,
though, have the same imaging requirement, an
enlarged pancreas with diffuse irregular narrowing of
the pancreatic duct [3-5].
Elevated IgG4 levels in AIP
In addition to the imaging and histologic characteristics
of AIP, a sensitive and specific serologic association with
elevated IgG4 serum levels was first described by
Hamano et al. [6]. A serum IgG4 level of at least 135
mg/dL resulted in 95% sensitivity and 97% specificity in
differentiating between AIP (referred to as sclerosing
pancreatitis in Hamano et al., and diagnosed by imaging,
histology, and response to steroids) and pancreatic can-
cer. They did not find elevated serum IgG4 levels in
patients with chronic pancreatitis, primary biliary cirrho-
sis, primary sclerosing cholangitis, nor Sjogren syndrome
[6]. These findings were supported by investigators at
the Mayo Clinic; using a serum IgG4 level cutoff of 140
mg/dL, the sensitivity for AIP was 76% and specificity
93%. Moreover, the negative predictive value of serum
IgG4 <140 mg/dL was 99%, but the positive predictive
value was only 36% [20]. In both the Mayo Clinic cohort
[20] and the Hamano et al. cohort [6], 3-10% of patients
without AIP had elevations in serum IgG4, and in the
Mayo Clinic cohort 11/45 (24%) patients with AIP had
normal serum IgG4 levels. All patients diagnosed with
AIP regardless of serum IgG4 levels had similar clinical
responses to corticosteroids. The patients most likely to
have normal IgG4 levels with a histologic diagnosis of
AIP were more likely to be female, younger, and less
likely to have other organ involvement. In addition, all
patients in the Mayo Clinic cohort that had normal
serum IgG4 levels and available histology had positive
IgG4 immunostaining [20].
IgG4 immunostaining has become a method to both
confirm pancreatic histology consistent with AIP and
evaluate other manifestations of a similar disease pro-
cess. In the study by Ghazale et al. [20], 19/20 patients
who had IgG4 immunostaining of pancreatic tissue
showed >10 IgG4 positive cells/hpf. Five patients with
elevated serum IgG4 levels that did not have AIP by
histology, had IgG4 immunostaining performed that was
negative in four patients ands h o w e dn o n s p e c i f i cf o c a l
clusters of IgG4 positive cells in one patient [20]. In
another cohort, all 21 AIP patients with pancreatic
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tive cells/hpf, and extrapancreatic specimens with lym-
phoplasmacytic infiltrate (3 biliary, 2 pulmonary, 3
salivary glands, 4 renal) when tested also showed signifi-
cant IgG4 positive cells by immunostaining (3 biliary, 1
lung, 1 salivary gland, 4 renal) [21]. Since the pathology
of the extrapancreatic lesions is the same as the pan-
creatic pathology, the concept of IgG4 related systemic
disease was developed. Whether or not distinct cate-
gories of AIP based on IgG4 levels will be established in
pediatric cases is yet to be determined.
Extrapancreatic manifestations of IgG4 related disease
Elevated serum IgG4 levels and positive IgG4 immunos-
taining have been associated not only with AIP, but also
with retroperitoneal fibrosis, sialoadenitis, mediastinal
adenopathy (as in the patient reported herein), cholangi-
tis, and tubulointerstitial nephritis [3,21,22,27] and is
one criterion for diagnosis in the HISORt criteria [3,5].
In 12 patients clinically diagnosed with idiopathic retro-
peritoneal fibrosis, 16 biopsies (retroperitoneal tissue,
liver, kidney, colon, omentum) showed fibrosis with a
lymphoplasmacytic infiltrate, and 14/16 biopsies had
IgG4 positive plasma cells (not seen in one liver and
one colon biopsy). Comparative biopsies from inflamma-
tory and fibrotic diseases in similar organs failed to
show any IgG4 positive cells [27]. Ghazale et al. [22]
reported 4 patients with IgG4 positive immunostaining
on bile duct resection with histology comparative to
AIP, namely, lymphoplasmacytic infiltrate with storiform
fibrosis and obliterative phlebitis around the bile duct,
who had no evidence of pancreatic disease or involve-
ment. Similarly, these patients responded to corticoster-
oids with improvement in all and resolution of strictures
in most. Some patients, however, had relapse with corti-
costeroid taper, but instead of continuing low dose ther-
apy they were started on other immunomodulatory
medications, azathioprine, MMF, or cyclophosphamide
with successful maintenance of treatment [22]. The
similar pathology, immunostaining, and response to
steroids have led to the proposal of an IgG4-related
sclerosing disease, of which AIP is the pancreatic mani-
festation of a systemic process [7,21,23,27].
Treatment of AIP
Prior to the concept of AIP, patients with painless swelling
of the pancreas were treated with surgery to rule out a
malignant process. The histologic specimens collected fol-
lowing resection, where malignancy was ruled out and an
inflammatory infiltrate was noted instead, have been used
to create the Mayo Clinic HISORt criteria [3]. Yoshida et
al. [2] was the first to report the successful use of corticos-
teroids in a patient with AIP, resulting in resolution
of symptoms, imaging abnormalities, and laboratory
abnormalities. A resolution or at least effective response to
corticosteroids is part of the Mayo Clinic HISORt diagnos-
tic criteria and is noted as a characteristic of AIP in the
JPS criteria [3-5].
As the concept of AIP as part of a systemic IgG4
related disease developed, so did the need for more
aggressive treatment. In most cases of AIP, patients
respond fully to a single course of corticosteroids
[2,3,25]; however, some patients with AIP, and especially
those with extrapancreatic manifestations (including our
patient), are unable to fully wean off of corticosteroids
[22,25,27]. Azathioprine and low dose prednisone have
been used to control symptoms and limit disease course
with success [27]; in addition, MMF and cyclophospha-
mide have also been used in cases of IgG4 associated
cholangitis (IAC) with successful maintenance of remis-
s i o n[ 2 2 ] .M M Fh a sa l s ob een used successfully in
patients with idiopathic retroperitoneal fibrosis (there
was no mention of IgG4 testing or staining in this case
series) [28]. These patients were initially started on pre-
dnisone and MMF, the prednisone was weaned off over
6 months, and MMF was discontinued after 11-96
months (mean 27 months). All 9 patients had regression
of disease and improvement in inflammatory markers;
there was no recurrence after discontinuation of medical
therapy. In vitro lab work has demonstrated that MMF
has direct antifibrotic properties by inhibiting type I
collagen production, altering the contractile and migratory
functions of fibroblasts, and enhancing the production of
matrix metalloproteinase (interstitial collagenase) [29].
Thus, MMF seems a logical choice in treating autoim-
mune fibrosing disorders.
Pediatric Reports
There are 7 other pediatric patients reported in the lit-
erature with AIP or likely AIP (Table 3) by JPS or
HISORt criteria. Only one had normal imaging [14] (she
w a su n a b l et ob ed i a g n o s e da sA I Pb yJ P So rH I S O R t
criteria, but did respond to steroid therapy and had an
elevated IgG4), and 4 of the 7 patients had histology
reported, all 4 consistent with AIP [8-10,13]. The only
patient with an elevated IgG4 was the patient who did
not meet diagnostic criteria for AIP [14]; she also had
an elevated total IgG level. One other patient had an
elevated IgG level, but normal IgG4 level [12], and one
patient did not have any laboratory work reported [13].
The other pediatric patients reported in the literature
with AIP or likely AIP (Table 3) were treated with corti-
costeroids or pancreatoduodenectomy with mixed
success. One patient requires daily steroids [12], treatment
is not reported in one [10], the surgical patient requires
digestive enzymes [13], and one patient requires NPH
insulin for diabetes but did not have recurrence of disease
[9]. There are many reports of IFP in the literature, but
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criteria consistent with AIP (Table 3) [15-18]. These
patients were treated with surgical resection [15,17],
observation (following diagnostic exploratory laparotomy)
[16], or biliary stenting [18], all with resolution of symp-
toms. None of these patients had immunoglobulins
reported or were given corticosteroids. The extent of AIP
and IgG4-associated autoimmunity in children remains
unanswered at present.
Conclusions
The patient presented in this report is diagnosable with
AIP by both JPS and HISORt (group B or C) diagnostic
criteria [3-5]. She also had an elevated IgG4 with
evidence of extrapancreatic manifestations, consistent
with IgG4 related systemic disease (ISD), even though
IgG4 staining was not done (Table 1 and 2). Her symp-
toms improved with corticosteroids, but she was unable
to wean off of them without disease flare and did not
want to continue due to system i cs i d ee f f e c t s .S h ew a s
successfully treated with MMF for one year with resolu-
tion of symptoms and evidence of inactive disease by
imaging and laboratory studies for a total of 19 months,
until she was lost to follow up. Our patient represents
the first pediatric patient with elevated IgG4 who met
both JPS and HISORt criteria for AIP, and the first
pediatric patient with AIP/ISD who was successfully
treated with MMF.
The pediatric patients reported in the literature,
including the patient reported here, have a disease that
is similar to adult AIP/ISD. The imaging reports are
similar, histology (when available) is consistent with
AIP, and there is typically a good response to corticos-
teroids. The pediatric patients, however, more often
present with abdominal pain than the adult patients
(11/12 reported here), and when immunoglobulins are
m e a s u r e d ,t h e ya r em o r el i k e l yt ob en o r m a lt h a n
elevated. Our patient has criteria most similar to the
adult patients and criteria reported in the literature,
including an elevated IgG4 level which is only reported
in one other pediatric patient, a patient that did not
meet diagnostic criteria for AIP [14]. This current
report demonstrates that while pediatric AIP/ISD is
very similar to adult AIP/ISD, it is not identical. As
reports of pediatric AIP/ISD increase, the criteria used
to diagnose adults may need to be modified to better
suit pediatric patients. Since pancreatic malignancy is
significantly rarer in pediatric patients than adult
patients, the criteria could likely be more inclusive
without the risk of delaying treatment for cancer. If
AIP/ISD were a more likely diagnosis in pediatric
patients with pancreatitis, corticosteroid therapy could
be attempted sooner and limit surgical interventions,
symptoms, and hopefully disease progression. In the
patients who do meet the adult criteria for AIP/ISD
who are unable to wean off of corticosteroids or who
cannot tolerate the side effects, other immunomodula-
tory medications should be considered. Our patient
responded fully to 1 year of treatment with MMF, was
symptom free at 19 months follow up with normal
imaging and IgG4 levels.
Consent
Institutional Review Board approval was attained. The
patient and her family have been lost to contact.
Repeated attempts at contact, including via her gastro-
enterologist, have failed.
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